Pembrolizumab Given Concomitantly with Chemoradiation and as Maintenance Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: KEYNOTE-412
Year: 2020
Type: article
Study design: Study Protocol
Abstract: Current treatment guidelines for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) recommend multimodal treatment, including chemoradiation therapy (CRT) or surgery followed by radiation, with or without chemotherapy. The immune checkpoint inhibitor pembrolizumab has previously demonstrated antitumor activity in recurrent and/or metastatic HNSCC in large Phase III trials. For patients with locally advanced disease, Phase Ib data on the use of pembrolizumab in combination with chemoradiation have shown the approach to be safe and feasible. We describe here the design and rationale for KEYNOTE-412, a randomized, double-blind, Phase III trial investigating pembrolizumab or placebo administered concurrently with CRT and as maintenance treatment in patients with locally advanced HNSCC. Clinical Trial Registration: NCT03040999 (ClinicalTrials.gov).
Source: Future Oncology
Authors: Jean-Pascal Machiels, Yungan Tao, Barbara Burtness, Makoto Tahara, Lisa Licitra, Danny Rischin, John Waldron, Christian Simon, Vincent Gregoire, Kevin Harrington, Gustavo Vasconcelos Alves, Iane Pinto Figueiredo Lima, Yoann Pointreau, Brett G M Hughes, Sercan Aksoy, Marcin Hetnal, Joy Y Ge, Holly Brown, Jonathan Cheng, Behzad Bidadi, Lillian L Siu
Institutions: Cliniques Universitaires Saint-Luc, UCLouvain, Institut Gustave Roussy, Yale Cancer Center, Yale University, National Cancer Center Hospital East, University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori, Peter MacCallum Cancer Centre, University of Toronto, Princess Margaret Cancer Centre, Centre Hospitalier Universitaire Vaudois, Hôpital Orthopédique de la Suisse Romande, Centre Léon Bérard, Institute of Cancer Research, Hospital Nossa Senhora da Conceição, Centre Jean Bernard, Clinique Victor Hugo, The University of Queensland, Royal Brisbane and Women's Hospital, Hacettepe University, Andrzej Frycz Modrzewski Krakow University, Merck & Co., Inc., Rahway, NJ, USA (United States), University Health Network
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W3032832010
